Trial
NCT06681870
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
CLDN6-positive Solid Tumor
Intervention
ASP1893
Why stopped
A business decision was made to not initiate this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-15